Evidence map›Paper›PMID 35935360›Full record

ArticleFrontiers in pediatrics2022

Hypoparathyroidism-retardation-dysmorphism syndrome-Clinical insights from a large longitudinal cohort in a single medical center.

Odeya David, Rotem Agur, Rosa Novoa, David Shaki, Dganit Walker, Lior Carmon, Marina Eskin-Schwartz, Ohad S Birk, Galina Ling, Ruth Schreiber and 3 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Expanding the Phenotypic Spectrum of Kenny-Caffey Syndrome.The Journal of clinical endocrinology and metabolism · 2023
    Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Odeya DavidPediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Rotem AgurFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Rosa NovoaDiagnostic Radiology Department, Soroka University Medical Center, Beer Sheva, Israel.
David ShakiPediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Dganit WalkerPediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Lior CarmonPediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Marina Eskin-SchwartzFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Ohad S BirkFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Galina LingFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Ruth SchreiberFaculty of Health Sciences, Ben-Gurion University of the Negev, Beer Sheva, Israel.
Neta LoewenthalPediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Alon HaimPediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Eli HershkovitzPediatric Endocrinology Unit, Saban Pediatric Medical Center for Israel, Soroka University Medical Center, Beer Sheva, Israel.
Ben-Gurion University of the Negev · ILSoroka Medical Center · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hypoparathyroidism, retardation, and dysmorphism (HRD) Syndrome is a rare disease composed of hypoparathyroidism, retardation of both growth and development, and distinctive dysmorphic features. Here, we describe the long-term morbidity and mortality in a large cohort of HRD patients and suggest recommendations for follow up and treatment. Methods: Medical records of 63 HRD syndrome patients who were followed at Soroka Medical Center during 1989-2019 were reviewed retrospectively. Information regarding demographics, medical complications, laboratory findings, and imaging studies was collected. Results: The mortality rate was 52%. The main causes of death were infectious diseases including pneumonia, septic shock, and meningitis. Multiple comorbidities were found including brain anomalies in 90% of examined patients (basal ganglia calcifications, tightening of corpus callosum, Chiari malformation, hydrocephalous, and brain atrophy), seizures in 62%, nephrocalcinosis and/or nephrolithiasis in 47%, multiple eye anomalies were recorded in 40%, bowel obstructions in 9.5%, and variable expression of both conductive and senso-neural hearing loss was documented in 9.5%. Conclusion: HRD is a severe multisystem disease. Active surveillance is indicated to prevent and treat complications associated with this rare syndrome.

Indexed as

bowel obstructionHRDinfectionsnephrolithiasisSanjad-Sakatiseizures

Identifiers

PMID35935360
PMCPMC9352926
OpenAlexW4286447898

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.